People · Operator
Named in public records as an officer, director or promoter · active 2009–2023 · Other, Biotechnology, Biotech / Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Sequenta, Inc. | — | Other | Series B | $44.9M | $332.3M | 2009 |
| Serimmune Inc. | — | Biotechnology | Series A | $27.5M | $83.5M | 2021 |
| Protillion Biosciences, lnc. | — | Biotech / Pharma | Series B | $19.0M | $256.6M | 2022 |
Malek Faham at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Malek Faham on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Rowan Chapman | 1 | 7 |
| David Walt | 1 | 6 |
| Bill Ericson | 1 | 5 |
| Nicholas Naclerio | 1 | 5 |
| Jim Tananbaum | 1 | 4 |
| John Stuelpnagel | 1 | 3 |
| Noah Nasser | 1 | 3 |
| Thomas Willis | 1 | 3 |
| Jacob Goldfield | 1 | 2 |
| Kristin Loomis | 1 | 2 |
| Sean Kendall | 1 | 2 |
| Nick Naclerio | 1 | 1 |
| Curtis Layton | 1 | 1 |
| Karen Kirk | 1 | 1 |
| Ephraim Gildor | 1 | 1 |
| Kirstin Loomis | 1 | 1 |
| Bill Welch | 1 | 1 |
| Patrick Daugherty | 1 | 1 |
| John Shon | 1 | 1 |
| Stephen M. Kujawa | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.